Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer.

The authors of the AVETUX trial also identified a certain subpopulation of patients, specifically those with the FcγR3a V-allele [ 56 ], that showed a trend towards clinical benefit in otherwise unsuccessful drug combinations, concluding that further research into these subpopulations may yield interesting results.

also in 53,322 other papers